| Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) (NCT06879145) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-04-25 |
| SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer (NCT06859775) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-04-25 |
| Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma (NCT06970145) | Nanfang Hospital, Southern Medical University | 2025-04-25 |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP (NCT07027111) | Nuvig Therapeutics, Inc. | 2025-04-25 |
| Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment (NCT06696183) | Technische Universität Dresden | 2025-04-25 |
| Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis (NCT06933238) | Dongzhimen Hospital, Beijing | 2025-04-25 |
| A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome (NCT07413978) | Changchun Tuohua Pharmaceutical Co., Ltd. | 2025-04-25 |
| A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC (NCT06925516) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2025-04-25 |
| Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma (NCT07047001) | Dong Wen | 2025-04-24 |
| A Trial of HRS-6768 in Patients With Advanced Solid Tumors (NCT06925581) | Jiangsu HengRui Medicine Co., Ltd. | 2025-04-24 |
| A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors (NCT06922357) | Shandong Suncadia Medicine Co., Ltd. | 2025-04-24 |
| Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases (NCT06401824) | Maastricht University Medical Center | 2025-04-24 |
| A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (NCT06820463) | AbbVie | 2025-04-24 |
| Family Acceptance Project Online (Pilot RCT) (NCT06839859) | University of Michigan | 2025-04-24 |
| Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT07140328) | Haisco Pharmaceutical Group Co., Ltd. | 2025-04-24 |
| GR1803 Injection in Patients With RRMM (NCT06952075) | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 2025-04-24 |
| A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME） (NCT06908876) | Innovent Biologics Technology Limited (Shanghai R&D Center) | 2025-04-24 |
| A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease (NCT06881836) | Ono Pharmaceutical Co., Ltd. | 2025-04-24 |
| Brain Signal Training to Enhance Affect Down-regulation (NCT06626789) | Central Institute of Mental Health, Mannheim | 2025-04-23 |
| A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's (NCT06928142) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-04-23 |
| A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer (NCT06885385) | Shanghai Junshi Bioscience Co., Ltd. | 2025-04-23 |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma (NCT06232044) | Alliance for Clinical Trials in Oncology | 2025-04-23 |
| Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (NCT06829771) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-04-23 |
| To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis (NCT07061925) | Korea Arlico Pharm. Co., Ltd | 2025-04-23 |
| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer (NCT06827236) | BioNTech SE | 2025-04-23 |
| Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects (NCT07024212) | Zhejiang Doer Biologics Co., Ltd. | 2025-04-22 |
| Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis (NCT06704269) | Novartis Pharmaceuticals | 2025-04-22 |
| Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT07117760) | First Affiliated Hospital of Fujian Medical University | 2025-04-22 |
| A Phase IIa Study to Evaluate NBQ72S (NCT06810804) | Nantong Bencao Quadriga Medical Technology Co. Ltd. | 2025-04-22 |
| NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial (NCT07077551) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2025-04-22 |
| An Interventional Study of Infigratinib in Children With Hypochondroplasia (NCT06873035) | QED Therapeutics, a BridgeBio company | 2025-04-22 |
| A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors (NCT06669975) | AP Biosciences Inc. | 2025-04-22 |
| Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage (NCT04696523) | Turku University Hospital | 2025-04-22 |
| A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors (NCT07172802) | GI Innovation, Inc. | 2025-04-22 |
| Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome (NCT07039747) | University Hospital, Rouen | 2025-04-22 |
| A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease (NCT06900010) | Shandong First Medical University | 2025-04-22 |
| Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) (NCT06926842) | Zealand Pharma | 2025-04-22 |
| A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06857279) | Shanghai Henlius Biotech | 2025-04-22 |
| Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy (NCT06902896) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2025-04-22 |
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma (NCT06854003) | Christine Ryan | 2025-04-22 |
| SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases (NCT06850103) | First Affiliated Hospital of Zhejiang University | 2025-04-22 |
| A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients (NCT06879717) | iOnctura | 2025-04-22 |
| Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma (NCT06987916) | Shanghai Tongji Hospital, Tongji University School of Medicine | 2025-04-22 |
| MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC (NCT07235566) | Fudan University | 2025-04-21 |
| AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer (NCT06938503) | Tianjin Medical University Cancer Institute and Hospital | 2025-04-21 |
| 4-AP Peripheral Nerve Crossover Trial (NCT06003166) | University of Arizona | 2025-04-21 |
| SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC (NCT07131319) | Second Affiliated Hospital of Nanchang University | 2025-04-21 |
| A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (NCT06897930) | AstraZeneca | 2025-04-21 |
| Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse (NCT06609369) | Yale University | 2025-04-21 |
| Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) (NCT06512220) | Centre for Addiction and Mental Health | 2025-04-21 |
| Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study (NCT06946836) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-04-21 |
| A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis (NCT06923228) | CAGE Bio Inc. | 2025-04-21 |
| TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC (NCT06914297) | Fudan University | 2025-04-21 |
| In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial (NCT06704191) | Mayo Clinic | 2025-04-21 |
| Metformin in Safety and Efficacy in Gouty Patients (NCT06924658) | Mostafa Bahaa | 2025-04-20 |
| Evaluation of the Modified VISTA Technique Using ALB-PRF vs CTG in the Treatment of Multiple Miller Class III Recessions (NCT06643507) | Cairo University | 2025-04-20 |
| A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma (NCT06356688) | Sun Jing | 2025-04-20 |
| Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study (NCT07163910) | baotai Liang | 2025-04-20 |
| PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer (NCT06933251) | Guangdong Provincial People's Hospital | 2025-04-20 |
| Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） (NCT06924398) | Sun Yat-sen University | 2025-04-20 |
| Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh (NCT06817031) | International Centre for Diarrhoeal Disease Research, Bangladesh | 2025-04-20 |
| Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC (NCT06810609) | University Hospital, Bonn | 2025-04-20 |
| Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases (NCT07134153) | Fudan University | 2025-04-18 |
| IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer (NCT06770439) | Zhejiang University | 2025-04-18 |
| An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique (NCT06865768) | Emory University | 2025-04-18 |
| Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma (NCT06911255) | Yoon Jun Kim | 2025-04-18 |
| A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type) (NCT06962267) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 2025-04-18 |
| A Study of MT-4561 in Patients With Various Advanced Solid Tumors (NCT06943521) | Tanabe Pharma America, Inc. | 2025-04-18 |
| IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (NCT06974812) | Innovent Biologics (Suzhou) Co. Ltd. | 2025-04-18 |
| Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer (NCT05672095) | City of Hope Medical Center | 2025-04-18 |
| Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning (NCT06815003) | City of Hope Medical Center | 2025-04-18 |
| CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH (NCT06947460) | Beijing GoBroad Hospital | 2025-04-18 |
| GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies (NCT06948981) | Grit Biotechnology | 2025-04-18 |
| GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma (NCT06605131) | Sun Yat-sen University | 2025-04-17 |
| Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older (NCT06907511) | Sanofi | 2025-04-17 |
| Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC (NCT06935188) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2025-04-17 |
| Cultural Adaptation of a Web-Based App (myPlan Thailand) to Empower and Support Friends and Family of Intimate Partner Violence Survivors (NCT06934174) | Boromarajonani College of Nursing, Khon Kaen | 2025-04-17 |
| A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma. (NCT07448831) | Universitair Ziekenhuis Brussel | 2025-04-17 |
| A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study. (NCT07264673) | Fondazione Ricerca Traslazionale | 2025-04-17 |
| Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults (NCT06919926) | Johns Hopkins University | 2025-04-17 |
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) (NCT06951217) | Avalyn Pharma Inc. | 2025-04-17 |
| FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis (NCT06801665) | Hua Jiang | 2025-04-17 |
| Improving Coronary Vascular Health in Women (NCT06843902) | Massachusetts General Hospital | 2025-04-17 |
| SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC (NCT06927180) | Henan Cancer Hospital | 2025-04-16 |
| A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL (NCT06921044) | Xiaohui He | 2025-04-16 |
| Peritoneal Ultrafiltration in Cardio Renal Syndrome. (NCT03994874) | Iperboreal Pharma Srl | 2025-04-16 |
| REGN5381 in Adult Participants With Uncontrolled Hypertension (NCT06833190) | Regeneron Pharmaceuticals | 2025-04-16 |
| A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer (NCT07101679) | West China Hospital | 2025-04-16 |
| HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy (NCT06844669) | Washington University School of Medicine | 2025-04-16 |
| A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients (NCT06832202) | Shanghai Henlius Biotech | 2025-04-16 |
| Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study (NCT06975085) | University of Colorado, Denver | 2025-04-16 |
| A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (NCT06957080) | EyeBiotech Ltd. | 2025-04-16 |
| Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain (NCT06837857) | Mayo Clinic | 2025-04-16 |
| Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) (NCT06814145) | Merck Sharp & Dohme LLC | 2025-04-16 |
| Efficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura (NCT06720259) | Jennifer Keiser | 2025-04-16 |
| A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years (NCT06735248) | ModernaTX, Inc. | 2025-04-16 |
| Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome (NCT06842524) | Shanghai Zhongshan Hospital | 2025-04-16 |
| LSD to Improve Cluster Headache Impact Trial (NCT05477459) | Radboud University Medical Center | 2025-04-16 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer (NCT06528210) | OHSU Knight Cancer Institute | 2025-04-16 |
| Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites (NCT06919523) | Mansoura University | 2025-04-15 |